These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

114 related items for PubMed ID: 6979651

  • 1. 2'-Deoxycoformycin-induced hemolysis in the mouse.
    Spremulli E, Crabtree GW, Dexter DL, Diamond I, Calabresi P.
    J Natl Cancer Inst; 1982 Jun; 68(6):1011-4. PubMed ID: 6979651
    [Abstract] [Full Text] [Related]

  • 2. Toxicity and immunosuppressive activity of binary combinations of 2'-deoxycoformycin and 2'-deoxyadenosine.
    Paine RM, Weston BJ, Clink HM, Kohn J, Neville AM, McGhee KG, Harrap KR.
    Cancer Treat Rep; 1981 Jun; 65(3-4):259-66. PubMed ID: 6972254
    [Abstract] [Full Text] [Related]

  • 3. Levels of 2'-deoxycoformycin, adenosine, and deoxyadenosine in patients with acute lymphoblastic leukemia.
    Venner PM, Glazer RI, Blatt J, Sallan S, Rivera G, Holcenberg JS, Lipton J, Murphy SB, Poplack DG.
    Cancer Res; 1981 Nov; 41(11 Pt 1):4508-11. PubMed ID: 6975654
    [Abstract] [Full Text] [Related]

  • 4. Biochemical pharmacology and toxicology of formycin alone and in combination with 2'-deoxycoformycin (pentostatin).
    Spremulli EN, Crabtree GW, Dexter DL, Chu SH, Farineau DM, Ghoda LY, McGowan DL, Diamond I, Parks RE, Calabresi P.
    Cancer Treat Rep; 1983 Mar; 67(3):267-74. PubMed ID: 6600968
    [Abstract] [Full Text] [Related]

  • 5. Effects of deoxycoformycin in mice. II. Differences between the drug sensitivities and purine metabolizing enzymes of transplantable lymphomas of varying immunologic phenotypes.
    Ratech H, Kim J, Asofsky R, Thorbecke GJ, Hirschhorn R.
    J Immunol; 1984 Jun; 132(6):3077-84. PubMed ID: 6202772
    [Abstract] [Full Text] [Related]

  • 6. Phase I study of 2'-deoxycoformycin in acute lymphoblastic leukemia.
    Poplack DG, Sallan SE, Rivera G, Holcenberg J, Murphy SB, Blatt J, Lipton JM, Venner P, Glaubiger DL, Ungerleider R, Johns D.
    Cancer Res; 1981 Sep; 41(9 Pt 1):3343-6. PubMed ID: 6973390
    [Abstract] [Full Text] [Related]

  • 7. Deoxycoformycin: neurological toxicity.
    Major PP, Agarwal RP, Kufe DW.
    Cancer Chemother Pharmacol; 1981 Sep; 5(3):193-6. PubMed ID: 6975188
    [Abstract] [Full Text] [Related]

  • 8. Specific immunosuppressive effects of constant infusion of 2'-deoxycoformycin.
    Trotta PP, Tedde A, Ikehara S, Pahwa R, Good RA, Balis ME.
    Cancer Res; 1981 Jun; 41(6):2189-96. PubMed ID: 6972248
    [Abstract] [Full Text] [Related]

  • 9. Neurotoxicity of deoxycoformycin: effect of constant infusion on adenosine deaminase, adenosine, 2'-deoxyadenosine and monoamines in the mouse brain.
    Helland S, Broch OJ, Ueland PM.
    Neuropharmacology; 1983 Jul; 22(7):915-7. PubMed ID: 6604884
    [Abstract] [Full Text] [Related]

  • 10. 2'-deoxycoformycin toxicity in murine spleen lymphocytes.
    Earle MF, Glazer RI.
    Mol Pharmacol; 1983 Jan; 23(1):165-70. PubMed ID: 6602939
    [No Abstract] [Full Text] [Related]

  • 11. Association of severe and fatal infections and treatment with pentostatin.
    O'Dwyer PJ, Spiers AS, Marsoni S.
    Cancer Treat Rep; 1986 Sep; 70(9):1117-20. PubMed ID: 3488805
    [Abstract] [Full Text] [Related]

  • 12. Hemolysis in mice treated with deoxycoformycin, an inhibitor of adenosine deaminase.
    Smith CM, Belch A, Henderson JF.
    Biochem Pharmacol; 1980 Apr 15; 29(8):1209-10. PubMed ID: 6966932
    [No Abstract] [Full Text] [Related]

  • 13. DNA strand breaks induced in human T-lymphocytes by the combination of deoxyadenosine and deoxycoformycin.
    Brox L, Ng A, Pollock E, Belch A.
    Cancer Res; 1984 Mar 15; 44(3):934-7. PubMed ID: 6607110
    [Abstract] [Full Text] [Related]

  • 14. Effects of deoxycoformycin in mice. I. Suppression and enhancement of in vivo antibody responses to thymus-dependent and -independent antigens.
    Ratech H, Bell MK, Hirschhorn R, Thorbecke GJ.
    J Immunol; 1984 Jun 15; 132(6):3071-6. PubMed ID: 6609968
    [Abstract] [Full Text] [Related]

  • 15. Alterations in erythrocyte adenine nucleotide pools resulting from 2'-deoxycoformycin therapy.
    Koller CA, Mitchell BS.
    Cancer Res; 1983 Mar 15; 43(3):1409-14. PubMed ID: 6600652
    [Abstract] [Full Text] [Related]

  • 16. S-adenosylhomocysteine catabolism and basis for acquired resistance during treatment of T-cell acute lymphoblastic leukemia with 2'-deoxycoformycin alone and in combination with 9-beta-D-arabinofuranosyladenine.
    Hershfield MS, Kredich NM, Koller CA, Mitchell BS, Kurtzberg J, Kinney TR, Falletta JM.
    Cancer Res; 1983 Jul 15; 43(7):3451-8. PubMed ID: 6601986
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Comparison of the effects on cultured L1210 leukemia cells of the ribosyl, 2'-deoxyribosyl, and xylosyl homologs of tubercidin and adenosine alone or in combination with 2'-deoxycoformycin.
    Cass CE, Selner M, Tan TH, Muhs WH, Robins MJ.
    Cancer Treat Rep; 1982 Feb 15; 66(2):317-26. PubMed ID: 6976834
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.